Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma

Tumori

Volumn 96, Issue 4, 2010, Pages 627-628

  De Dosso, Sara ^a   Martin, Vittoria ^b   Zanellato, Elena ^b   Frattini, Milo ^b   Saletti, Piercarlo ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Anal cancer; Cetuximab; EGFR; K Ras

Indexed keywords

CARBOPLATIN; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; MITOMYCIN C; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADVANCED CANCER; AGED; ANUS CARCINOMA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CODON; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; INGUINAL LYMPH NODE; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MUTATION; PELVIS; RADIATION DOSE; RASH; RECTUM ABDOMINOPERINEAL RESECTION; REFRACTORY SQUAMOUS CELL ANAL CARCINOMA; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR BIOPSY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; DISEASE COURSE; METABOLISM; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 77957189748     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600419     Document Type: Article

References (11)

1. Nigro ND, Seydel HG, Considine B, Vaitkevicius VK, Leichman L, Kinzie JJ: Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer, 51: 1826-1829, 1983.
2. Jaiyesimi IA, Pazdur R: Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol, 16: 536-540, 2003.
3. Evans TR, Mansi JL, Glees JP, Dalgleish AG, Knight MJ: Response of metastatic anal carcinoma to single agent carboplatin. Clin Oncol, 5: 57-58, 1993.
4. Fisher WB, Herbst KD, Sims JE, Critchfield CF: Metastatic cloacogenic carcinoma of the anus: sequential responses to adriamycin and cis-dichlorodiammineplatinum(II). Cancer Treat Rep, 62: 91-97,1978.
5. Grifaichi F, Padovani A, Romeo F Trinca C, Moscetti L, Cortesi E: Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report. Tumori, 87: 58-59, 2001. (Pubitemid 32273854)
6. Alvarez G, Perry A, Tan BR, Wang HL: Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol, 19: 942-949, 2006. (Pubitemid 43910473)
7. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 360: 1408-1417, 2009.
8. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler P, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F: Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol, 20: 1667-1673, 2009.
9. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol, 16: 2171-2177, 2007. (Pubitemid 46954639)
10. Phan LK, Hoff PM: Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum, 50: 395-398, 2007.
11. Sobrero AF, Maurel J, Fehrenbacher L Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA: 3rd EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol, 26: 2311-2319, 2008.